[ad_1]
(RTTNews) – AbbVie (ABBV) said the exploratory analysis from Cohort 3 of the Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis suggested that the combination led to reductions in bone marrow fibrosis (BMF) and variant allele frequency (VAF) for common genetic mutations found in individuals with myelofibrosis that may indicate disease modification.
The findings were shared in an oral presentation at the 64th American Society of Hematology Annual Meeting & Exposition(ASH).
Preliminary safety analysis identified no new safety signals. Twenty-five (78 percent) patients reported one or more adverse events (AE).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
[ad_2]
Image and article originally from www.nasdaq.com. Read the original article here.